As previously disclosed, on June 3, 2025, the Nasdaq Listing Qualifications Department (the "Staff") notified Plus Therapeutics, Inc. (the "Company") that it was not in compliance with the requirement under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5 million in stockholders' equity (the "Minimum Stockholders' Equity Requirement"). The Company reported stockholders' equity (deficit) of ($23,641,000) in its Quarterly Report on Form 10-Qfor the period ended March 31, 2025, and, as a result, did not satisfy the Minimum Stockholders' Equity Requirement. As a result, the Staff determined to delist the Company's securities from Nasdaq, unless the Company timely requested an appeal of the Staff's determination to a Hearings Panel (the "Panel") pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series. The Company timely requested a hearing, which hearing took place as scheduled on July 15, 2025.

On July 22, 2025, the Panel issued a decision granting the Company's request for continued listing on Nasdaq, subject to the Company demonstrating compliance with (1) the Minimum Stockholders' Equity Requirement by August 14, 2025 by filing a timely public disclosure describing the transactions undertaken by the Company to achieve compliance and demonstrate long-term compliance with the Minimum Stockholders' Equity Requirement, and by providing an indication of its equity following those transactions, with the option of including in the public filing a balance sheet not older than 60 days with pro forma adjustments for any significant transactions or events occurring on or before the report date; and (2) Nasdaq Listing Rule 5550(a)(2) by having the closing bid price of the Company's common stock meet or exceed $1.00 per share for a minimum of 10 consecutive business days on or before September 8, 2025.